Immune Therapy: What Can We Learn From Acquired Resistance?
Sign Up to like & getrecommendations! Published in 2021 at "Lung Cancer"
DOI: 10.1007/978-3-030-74028-3_5
Abstract: Programmed death-1 (PD-1) pathway inhibitors have revolutionized the treatment of locally advanced and advanced non-small cell lung cancer (NSCLC). Response to these agents can be durable, but most patients will go on to develop resistance… read more here.
Keywords: immune therapy; therapy learn; resistance; acquired resistance ... See more keywords